Trial Profile
Randomized study as second-line chemotherapy in mUC patients between gemcitabine and docetaxel regimen and pembrolizumab.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 26 Jun 2018 New trial record